share_log

信達生物：授出購股權及非豁免關連交易 - 建議向董事授出受限制股份及授出受限制股份

INNOVENT BIO: GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES

香港交易所 ·  Mar 24 06:28
Summary by Moomoo AI
信達生物於2024年3月22日宣布，根據首次公開發售後僱員持股計劃的條款，向63名承授人（包括6名董事）授出總計4,416,644份購股權，有效期為十年。此外，公司亦向執行董事俞博士及奚先生授出總計3,510,500股受限制股份，並向4名獨立非執行董事授出總計96,461股受限制股份，均須待獨立股東批准。授出購股權及受限制股份旨在激勵及獎勵員工，並鼓勵他們提升公司及其股份的價值。所有授出均設有歸屬期及績效目標，並有回撥機制。此舉符合公司薪酬政策，旨在將公司與員工的利益緊密相聯，以激勵員工參與公司的策略制定及長期發展。建議向執行董事及獨立非執行董事授出的受限制股份，因涉及關連人士，根據上市規則第14A章，須遵守申報、公告及獨立股東批准規定。
信達生物於2024年3月22日宣布，根據首次公開發售後僱員持股計劃的條款，向63名承授人（包括6名董事）授出總計4,416,644份購股權，有效期為十年。此外，公司亦向執行董事俞博士及奚先生授出總計3,510,500股受限制股份，並向4名獨立非執行董事授出總計96,461股受限制股份，均須待獨立股東批准。授出購股權及受限制股份旨在激勵及獎勵員工，並鼓勵他們提升公司及其股份的價值。所有授出均設有歸屬期及績效目標，並有回撥機制。此舉符合公司薪酬政策，旨在將公司與員工的利益緊密相聯，以激勵員工參與公司的策略制定及長期發展。建議向執行董事及獨立非執行董事授出的受限制股份，因涉及關連人士，根據上市規則第14A章，須遵守申報、公告及獨立股東批准規定。
Sinda Bio announced on 22 March 2024 that it has granted a total of 4,416,644 share options to 63 underwriters (including 6 directors) under the terms of the initial public offering post-sale employee holding scheme for a period of ten years. In addition, the Company also granted a total of 3,510,500 restricted shares to the Executive Directors, Dr. Yu Yu and Mr. Yi, and granted a total of 96,461 restricted shares to four independent non-executive directors, subject to the approval of the independent shareholders. The granting of share options and restricted shares is intended to motivate and reward employees and encourage them to enhance the value of the company and its shares. All awards have an attribution period and performance targets, and there is a...Show More
Sinda Bio announced on 22 March 2024 that it has granted a total of 4,416,644 share options to 63 underwriters (including 6 directors) under the terms of the initial public offering post-sale employee holding scheme for a period of ten years. In addition, the Company also granted a total of 3,510,500 restricted shares to the Executive Directors, Dr. Yu Yu and Mr. Yi, and granted a total of 96,461 restricted shares to four independent non-executive directors, subject to the approval of the independent shareholders. The granting of share options and restricted shares is intended to motivate and reward employees and encourage them to enhance the value of the company and its shares. All awards have an attribution period and performance targets, and there is a callback mechanism. This move is in line with the company's remuneration policy, which aims to closely align the interests of the company with the interests of its employees to encourage employee participation in the company's strategic development and long-term development. Restricted shares granted to executive directors and independent non-executive directors are proposed to be subject to the reporting, announcement and independent shareholder approval requirements pursuant to Chapter 14A of the Listing Rules as they involve related persons.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more